secwatch / observer
8-K filed April 4, 2022, 7:59 PM ET ticker KBR CIK 0001357615
leadership confidence high sentiment neutral materiality 0.30

KBR board member Umberto della Sala to retire; Sir John Manzoni nominated as successor

KBR, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sir John A. Manzoni KCB

Director
KBR · KBR, INC.
Filed
April 4, 2022, 7:59 PM ET
The Board nominated Sir John A. Manzoni KCB (“Sir John”) to fill the vacancy that will be created by Mr. della Sala’s retirement.
Departed

Umberto della Sala

Director
KBR · KBR, INC.
Effective
2022-05-18
Successor
Sir John A. Manzoni
Filed
April 4, 2022, 7:59 PM ET
On April 1, 2022, Umberto della Sala informed KBR, Inc. (“KBR”) of his decision to retire from the KBR Board of Directors (“Board”) effective May 18, 2022, at the conclusion of KBR’s 2022 Annual Meeting of Stockholders (“Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sir John A. Manzoni KCB was appointed as Director at KBR, INC..

Action
nominated
Role
Director
Exact text from the filing
The Board nominated Sir John A. Manzoni KCB (“Sir John”) to fill the vacancy that will be created by Mr. della Sala’s retirement.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Umberto della Sala retired as Director at KBR, INC..

Action
retired
Role
Director
Exact text from the filing
On April 1, 2022, Umberto della Sala informed KBR, Inc. (“KBR”) of his decision to retire from the KBR Board of Directors (“Board”) effective May 18, 2022, at the conclusion of KBR’s 2022 Annual Meeting of Stockholders (“Annual Meeting”).
View on SEC.gov

KBR, INC. filing history →

Source: SEC EDGAR
accession 0001140361-22-012744
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.